The overall objective of the CAP study was to determine genetic influences on efficacy of
simvastatin treatment with regard to LDL cholesterol reduction and changes in other markers
of cardiovascular disease risk.
Phase:
Phase 4
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland UCSF Benioff Children's Hospital Oakland
Collaborators:
Cedars-Sinai Medical Center Duke University National Heart, Lung, and Blood Institute (NHLBI) San Francisco General Hospital University of California, Los Angeles University of Washington